meta
|
COVID-19
Evidence base on drug efficacy and safety
adjuvant therapies
anti-inflammatoty and immuno-therapy
anti-inflammatory therapies
Apilimod
corticosteroids
Immunostimulants drugs
Immunosuppressants drugs
inhaled corticosteroids
Kinase inhibitors
leflunomide
meplazumab
pirfenidone
Polyinosinic-Polycytidylic Acid
sargramostim
statins
thymosin
antiandrogenic
antiviral and associated therapy
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
Vitamins
All
COVID-19
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 prophylaxis (childrens)
COVID-19 prophylaxis (excluding childrens)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
patient subgroup...
Studies
Mapping
Meta-analysis
Excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded